ArticleFrontiers in psychiatry2026
Case Report: Diagnostic overshadowing in a patient with major depressive symptoms later diagnosed with systemic amyloidosis.
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The symptoms of depression may overlap with the early manifestations of systemic diseases, resulting in diagnostic masking. Amyloidosis is a multisystemic disease that has the potential to affect the heart, kidneys, nervous system, liver, lungs and intestines. Cardiac involvement is the leading cause of morbidity and mortality. As the symptoms of systemic amyloidosis can be non-specific and like those of a depressive episode in its early stages, there can be delays in diagnosis when patients are initially diagnosed depressed. Case presentation: We report the case of a 57-year-old male patient who was initially diagnosed with a major depressive episode. During treatment, he developed recurrent episodes of hypotension and syncope, which were initially attributed to his psychiatric condition and medication-related factors. As his clinical condition progressively deteriorated, a renal biopsy was performed, which ultimately confirmed a diagnosis of systemic amyloidosis with cardiac involvement and acute decompensated heart failure. Conclusion: This case suggests that, at the interface between psychiatry and somatic medicine, diagnostic overshadowing, anchoring bias, and fragmented care may jointly contribute to delayed recognition of systemic amyloidosis, particularly cardiac amyloidosis. In cases where patients present with depression-like manifestations, orthostatic hypotension, and nonspecific multisystem symptoms, clinicians should remain highly alert to persistently progressive physiological abnormalities and dynamically re-evaluate potential underlying somatic etiologies as new evidence emerges. Greater interdisciplinary awareness and reduced cognitive bias may help to reduce diagnostic delay and optimize multidisciplinary management. Further investigation is required to explain the mechanistic links between systemic amyloidosis and depressive symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.